



1685.  
#8

PATENT APPLICATION

Our File No.: 20020011.ORI

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Re App : John Collinge et al : August 14, 2002  
S.N. : 10/031,975 : Art Unit 1645  
Filed : January 24, 2002  
For : FRAGMENTS OF CELLULAR PRION PROTEIN  
AND METHODS USEFUL IN THE DIAGNOSIS  
AND TREATMENT OF PRION DISEASES

RECEIVED

AUG 22 2002

Hon. Commissioner of Patents and Trademarks  
Washington, D.C. 20231

TECH CENTER 1600/2900

Sir:

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

In recognition of the obligations imposed upon applicants and their attorneys and assigns under 37 CFR 1.56, the accompanying list identifies pertinent art related to the invention described in the above-identified application. The references listed on the attached Form PTO-1449 are cited for consideration by the Patent and Trademark Office.

This Supplemental Disclosure is being submitted pursuant to 37 CFR 1.97.

The references enclosed were received by applicants and were cited in the patent application.

A copy of each of the listed references is enclosed.

The Commissioner is authorized to charge any fees or refund any overpayment under 37 CFR 1.16 and 1.17 which may be required by this paper to Deposit Account No. 08-1265.

Dated: August 14, 2002

Respectfully submitted,

NIKOLAI & MERSEREAU, P.A.



C. G. Mersereau  
Attorney for Applicant(s)  
Registration No. 26,205  
900 Second Avenue South  
Suite 820  
Minneapolis, MN 55402  
Phone: 612-339-7461

#### CERTIFICATE OF MAILING

I hereby certify that the foregoing Supplemental Information Disclosure Statement Under Rule 1.56, Form PTO-1449 and a copy of each cited reference to be filed in connection with application Serial No. 10/031,975 of inventors, John Collinge et al, filed January 24, 2002, for "FRAGMENTS OF CELLULAR PRION PROTEIN AND METHODS USEFUL IN THE DIAGNOSIS AND TREATMENT OF PRION DISEASES" are being deposited with the United States Postal Service as First Class Mail in an envelope addressed to: Commissioner of Patents and Trademarks, Box DD, Washington, D.C. 20231 on August 14, 2002.



Barbara L. Davis  
Secretary to C. G. Mersereau

Date of Signature: August 14, 2002



(2-92)  
Sheet 1 of 3

Form PTO-1449  INFORMATION DISCLOSURE CITATION IN AN APPLICATION  (Use several sheets if necessary)	Document Number 20020011.ORI	Application Number 10/031,975
	Applicant John Collinge et al	
	Filing Date January 24, 2002	Group Art Unit 1645

RECEIVED

AUG 22 2002

U.S. PATENT DOCUMENTS

TECH CENTER 1600/2900

EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE

FOREIGN PATENT DOCUMENTS

	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	Translation	
						YES	NO

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Papers, Etc.)

	Bai et al., PROTEINS, <i>Primary Structure Effects on Peptide Group Hydrogen Exchange</i> , Vol. 17, (1993), pp. 75-86
	Bai et al, SCIENCE, <i>Protein Folding Intermediates: Native-State Hydrogen Exchange</i> , Vol. 269, July 14, 1995, pp. 192-197
✓	Billeter et al, PRO NATL ACAD SCI USA, <i>Prion Protein NMR Structure and Species Barrier for Prion Diseases</i> , Vol. 94, July 1997, pp. 7281-7285
	Booth et al, NATURE, <i>Ninstability, Unfolding and Aggregation of Human Lysozyme Variants Underlying Amyloid Fibrillogenesis</i> , Vol. 385, February 1997, pp. 787-793
	Collinge et al, LANCET, <i>Diagnosis of Gerstmann-Straussler Syndrome in Familial Dementia With Prion Protein Gene Analysis</i> , Vol. 2, July 1, 1989, pp. 15-17
	Collinge et al, LANCET, <i>Transmission of Fatal Familial Insomnia to Laboratory Animals</i> , (1995), Vol. 346, pp. 569-70
	Donne et al, PRO. NATL. ACAD. SCI. USA, <i>Structure of the Recombinant Full-Length Hamster Prion Protein PrP(29-231): The N Terminus is Highly Flexible</i> , Vol. 94, December 1997, pp. 13452-13457
	Hsiao et al., NATURE, <i>Linkage of a Prion Protein Missense Variant to Gerstmann-Straussler Syndrome</i> , Vol. 338, March 23, 1989, pp. 342-345
	Hayes et al, JOURNAL OF MOLECULAR BIOLOGY, <i>Engineered Assembly of Intertwined Oligomers of an Immunoglobulin Chain</i> , Vol. 285, (1999), pp. 1855-1865

EXAMINER	DATE CONSIDERED
----------	-----------------

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP § 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to the applicant.

(2-92)  
Sheet 2 of 3

Form PTO-1449  INFORMATION DISCLOSURE CITATION IN AN APPLICATION  (Use several sheets if necessary)	Document Number 20020011.ORI	Application Number 10/031,975
	Applicant John Collinge et al	
	Filing Date January 24, 2002	Group Art Unit 1645

AUG 22 2002

TECH CENTER 1600/290

## U.S. PATENT DOCUMENTS

EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE

## FOREIGN PATENT DOCUMENTS


DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	Translation YES   NO

## OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Papers, Etc.)

	Hornemann et al., PRO NAT'L ACAD SCI USA, A Scrapie-like Unfolding Intermediate of the Prion Protein Domain PrP(121-231) Induced by Acidic pH, Vol. 95, (1998), pp. 6010-6014
	Hosszu et al, NATURE STRUCTURAL BIOLOGY, Structural Mobility of the Human Prion Protein Probed by Backbone Hydrogen Exchange, Vol. 6(8), August 1999, pp. 740-743
	Jackson et al, SCIENCE, Reversible Conversion of Monomeric Human Prion Protein Between Native and Fibrillogenic Conformations, Vol. 283, March 19, 1999, p. 1935-1937
	James et al, PROC NATL ACAD SCI USA, Solution Struction of a 142-residue Recombinant Prion Protein Corresponding to the Infectious Fragment of the Scrapie Isoform, Vol. 94, September 1997, pp. 10086-10091
	Korth et al, NATURE, Prion (PrP <sup>Sc</sup> )-Specific Epitope Defined by a Monoclonal Antibody, Vol. 390, November 6, 1997, pp. 74-77
	Kascsak et al, JOURNAL OF VIROLOGY, Mouse Polyclonal and Monoclonal Antibody to Scrapie-Associated Fibril Proteins, Vol. 61, No. 12, pp. 3688-3698
	Kelly, CURRENT BIOLOGY LTD., Alternative Conformations of Amyloidogenic Proteins Govern Their Behavior, Vol. 6, (1996), pp. 11-17
	Murray et al, PROC NATL ACAD SCIE USA, One Sequence, Two Folds: A Metastable Structure of CD2, Vol. 92, August 1995, pp. 7337-7341
	Scott et al, PNAS, Identification of a Prion Protein Epitope Modulating Transmission of Bovine Spongiform Encephalopathy Prions to Transgenic Mice, Vol. 94, December 1997, pp. 14279-14284

EXAMINER	DATE CONSIDERED
----------	-----------------

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP § 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to the applicant.



(2-92)  
Sheet 3 of 3

Form PTO-1449  INFORMATION DISCLOSURE CITATION IN AN APPLICATION  (Use several sheets if necessary)	Document Number 20020011.ORI	Application Number 10/031,975
	Applicant John Collinge et al	
	Filing Date January 24, 2002	Group Art Unit 1645

U.S. PATENT DOCUMENTS

EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE

RECEIVED

AUG 22 2002

FOREIGN PATENT DOCUMENTS

TECH CENTER 1600/2900

	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	Translation YES   NO
	WO 98/16834	23/04/98	PCT			
	WO 98/37210	27/08/98	PCT			
	WO 98/55132	10/12/98	PCT			

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Papers, Etc.)

	Serban et al, NEUROLOGY, Rapid Detection of Creutzfeldt-Jakob Disease and Scrapie Prion Proteins, Vol. 40, (1990), pp. 110-117
	Wishart et al, JOURNAL OF BIOMOLECULAR NMR, Cthe <sup>13</sup> C Chemical-Shift Index: A Simple Method for the Identification of Protein Secondary Structure Using <sup>13</sup> C Chemical-Shift Data, Vol. 4, (1994), pp. 171-180
	Wishart et al, JOURNAL OF MOLECULAR BIOLOGY, Relationship Between Nuclear Magnetic Resonance Chemical Shift and Protein Secondary Structure, Vol. 222, (1991), pp. 311-333
	Zhang et al, BIOCHEMISTRY, Physical Studies of Conformational Plasticity in a Recombinant Prion Protein, Vol. 36 (1997), pp. 3543-3553

EXAMINER	DATE CONSIDERED
----------	-----------------

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP § 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to the applicant.